Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$27,000.00

Exploring the genome of natural killer cells to improve immunotherapies against multiple myeloma

EF 2024-25

Résumé
Multiple myeloma is an aggressive plasma cell cancer with limited treatment options and high mortality. Natural killer (NK) cells, part of the innate immune system, can intuitively recognize and attack cancer cells. For this reason, NK cells have become a promising avenue for immunotherapies targeting multiple myeloma. However, current NK therapies often lose their strength and stop fighting cancer cells effectively in the body. To make NK cells a more reliable cancer treatment, we need to find ways to keep them active and effective for longer. This research aims to discover key genes that make NK cells more effective at fighting multiple myeloma. First, in a cell culture model, well use CRISPR engineering to turn off genes across the NK cell genome, creating cells with different DNA modifications. These cells will then be tested to find populations that show stronger tumor-targeting abilities. We will analyze the DNA sequences of these high performing cells and identify promising genes that display prolonged persistence and increased targeting capacity. Next, well test these improved NK cells in a live model with multiple myeloma to see if the beneficial effects hold up in a more complex system. The multiple myeloma model will receive doses of engineered NK cells, and well track both the NK cells and tumor growth over time. Comparing the results to those from the current NK cell treatment will show whether our approach offers improved tumor-targeting effects. This study is innovative as large-scale gene screening in immune cells is under-researched. By pinpointing genes that strengthen NK cells, this research could identify new ways to use NK cells in cancer treatment, helping more patients with multiple myeloma and other cancer types in the future.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530062
Name
Stabile Cassandra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the genome of natural killer cells to improve immunotherapies against multiple myeloma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Cancer; Cell Therapy; Chimeric Antigen Receptor; Crispr; In Vivo Validation; Multiple Myeloma; Natural Killer Cells; Next Generation Sequencing; Whole-Genome Screen
Abstract
Multiple myeloma is an aggressive plasma cell cancer with limited treatment options and high mortality. Natural killer (NK) cells, part of the innate immune system, can intuitively recognize and attack cancer cells. For this reason, NK cells have become a promising avenue for immunotherapies targeting multiple myeloma. However, current NK therapies often lose their strength and stop fighting cancer cells effectively in the body. To make NK cells a more reliable cancer treatment, we need to find ways to keep them active and effective for longer. This research aims to discover key genes that make NK cells more effective at fighting multiple myeloma. First, in a cell culture model, well use CRISPR engineering to turn off genes across the NK cell genome, creating cells with different DNA modifications. These cells will then be tested to find populations that show stronger tumor-targeting abilities. We will analyze the DNA sequences of these high performing cells and identify promising genes that display prolonged persistence and increased targeting capacity. Next, well test these improved NK cells in a live model with multiple myeloma to see if the beneficial effects hold up in a more complex system. The multiple myeloma model will receive doses of engineered NK cells, and well track both the NK cells and tumor growth over time. Comparing the results to those from the current NK cell treatment will show whether our approach offers improved tumor-targeting effects. This study is innovative as large-scale gene screening in immune cells is under-researched. By pinpointing genes that strengthen NK cells, this research could identify new ways to use NK cells in cancer treatment, helping more patients with multiple myeloma and other cancer types in the future.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Stabile, Cassandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~